Competition will get severe between Viread and Baraclude

Expected to be applied for the insurance benefit on the solo therapy for multiple drug resistant patients, the Gilead’s hepatitis type B treatment, Viread (tenofovir), has kept its increasing curve.

It is expected that the product not only exceeded KRW 100 billion prescription expenses, meaning as the large pharmaceutical product in the domestic industry, but established the foundation to comp...